Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639406 | 0.79 | THRB (0.35) | NAAAIDO1AGXTTHRBCACNA1B | |
| SCHEMBL29773823 | 0.79 | NAAA (0.44) | NAAAIDO1AGXTTHRB | |
| SCHEMBL2385910 | 0.75 | THRB (0.36) | NAAAIDO1AGXTHRH3THRB | |
| SCHEMBL15032442 | 0.71 | NAAA (0.38) | NAAAIDO1AGXTTHRBREN | |
| SCHEMBL12151521 | 0.70 | IDO1 (0.37) | NAAAIDO1AGXTTHRBAPLNR | |
| SCHEMBL18287587 | 0.70 | NAAA (0.37) | NAAAIDO1AGXTTHRBAPLNR | |
| SCHEMBL12151520 | 0.70 | IDO1 (0.36) | NAAAIDO1AGXTTHRBREN | |
| SCHEMBL3863180 | 0.69 | PPM1D (0.32) | — | |
| SCHEMBL3863183 | 0.69 | PPM1D (0.32) | — | |
| SCHEMBL15007796 | 0.68 | IDO1 (0.37) | NAAAIDO1AGXTTHRBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015932-A1 | BIOORTHOGONAL COMPOSITIONS | TAMBO, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10828373-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828373-B2 | Bioorthogonal compositions | CD47, EPHA2, MSN | NAAA 2820/4885IDO1 1053/4885AGXT 2315/4885 |
| US-20210015932-A1 | BIOORTHOGONAL COMPOSITIONS | CD47, EPHA2, MSN | NAAA 2820/4885IDO1 1053/4885AGXT 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.